Program
quabodepistat
Also written as “Quabodepistat”, “OPC-167832 10 mg” and “OPC-167832 30 mg”.
Its studies are mostly in Tuberculosis, Pulmonary · Tuberculosis, Multidrug-Resistant · Tuberculosis, led by Otsuka.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsuka | 51 open or running | phase 3since Aug 12, 2025 | Sep 18, 2018 | Sep 29, 2028phase 3 · NCT07209761 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 18, 2018First study: phase 2 study in Tuberculosis, PulmonaryFirst studyNCT03678688 · 122 enrolled · South Africa
- Aug 20, 2021Phase 2 study in Tuberculosis, PulmonaryNCT05221502 · 122 enrolled · South Africa
- Aug 12, 2025Phase 3 study in Tuberculosis, Multidrug-ResistantNCT07209761 · 532 planned · China, Georgia, India and more
- Dec 18, 2025Phase 1 study in Healthy VolunteersNCT07314320 · 8 enrolled · United States
- Apr 14, 2026Phase 1 study in TuberculosisNCT07542847 · 24 enrolled · United States
- Oct 26, 2026Primary completion moved from 2027-05-28 to 2028-09-29Date moved laterphase 3 · +16 months · NCT07209761
Ahead
- Sep 29, 2028Primary completion: phase 3 study in Tuberculosis, Multidrug-ResistantNCT07209761
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07542847Tuberculosis · United States | 1 | Completed | Nov 18, 2022 | 24 |
| NCT07314320Healthy Volunteers · United States | 1 | Completed | Dec 27, 2023 | 8 |
| NCT07209761Tuberculosis, Multidrug-Resistant · China, Georgia, India and more | 3 | Recruiting | Sep 29, 2028 | 532 |
| NCT05221502Tuberculosis, Pulmonary · South Africa | 2 | Completed | Apr 8, 2024 | 122 |
| NCT03678688Tuberculosis, Pulmonary · South Africa | 2 | Completed | Feb 14, 2022 | 122 |
How it is read
Names in the registry
- “Quabodepistat”, 1 entry
- “OPC-167832 10 mg”, 1 entry
- “OPC-167832 30 mg”, 1 entry
- “OPC-167832 90 mg”, 1 entry
- “OPC-167832”, 1 entry
Codes read as this program: OPC167832.
Conditions, from the studies’ own filings
- Tuberculosis, Pulmonary, 2 studies
- Tuberculosis, Multidrug-Resistant, 1 study
- Tuberculosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.